Michael D. Prados MD, FACP
Professor in Residence of Neurological Surgery, Charles B. Wilson MD Endowed Chair
Director of Translational Research in Neuro-Oncology
Principal Investigator, Pediatric Brain Tumor Consortium
Principal Investigator, Brain Tumor Research Center
Director of the Department's Translational Research Program, Dr. Prados has over 20 years' experience at UCSF in treating and supervising the treatment of both adults and children who have brain tumors. The National Cancer Institute's Adult Brain Tumor Consortium, which sponsors trials of treatment regimens for brain tumors, is based at UCSF under Dr. Prados' leadership, and he is principal investigator of the Pediatric Brain Tumor Consortium site at UCSF, which is one of 7 institutions in the United States selected to participate in this NIH-funded cooperative effort to develop effective new strategies for treating children with malignant brain tumors.
Dr. Prados, both individually and in conjunction with multi-center and multidisciplinary clinical research efforts, supervises and participates in conducting extensive trials of clinical therapy for malignant brain tumors. He is the supervising preceptor training BTRC clinical fellows in conducting clinical trials and analyzing and interpreting clinical trial data. His research interest is in clinical research trials for primary brain tumors. Dr. Prados has been a principal investigator, co-investigator, or collaborating investigator in over 35 research protocols from the National Institutes of Health (NIH), UCSF, and Industry studies over the last several years, and currently is principal investigator or co-investigator of 4 active NIH grants.
Education, Training, and Previous Positions
- 1970: BS, University of New Orleans
1974; MD, Louisiana State University (LSU) School of Medicine
1974-1975: Internship in Medicine, Charity Hospital in New Orleans
1975-1977: Residency in Internal Medicine, LSU Earl K Long Hospital
1977-1978: Instructor, Internal Medicine, LSU School of Medicine
1979-1982: Assistant Professor, Internal Medicine, LSU School of Medicine
1983: Fellowship in Pulmonary Medicine, Tulane School of Medicine
1984-1985: Assistant Clinical Director of Pulmonary Medicine, Touro Hospital, Tulane University School of Medicine
1985-1987: Fellowship in Neuro-Oncology, University of California San Francisco
1985-1987: Clinical Instructor of Neurosurgery/Neuro-Oncology, Department of Neurological Surgery, UCSF
1987-1989: Acting Director of the UCSF Neuro-Oncology Service
1988-1991: Assistant Clinical Professor, Department of Neurological Surgery, UCSF
1989-2003: Director of the UCSF Neuro-Oncology Service
1991-1995: Associate Professor in Residence Neurological Surgery, UCSF
1995-present: Professor in Residence, Neurological Surgery, UCSF
2003-Present: Director of Translational Research, Neurological Surgery, UCSF
Selected Professional Memberships and Appointments
- American College of Physicians
American Society of Clinical Oncology
Children's Oncology Group
Associate editor, editorial reviewer: Journal of Neuro-Oncology
Associate editor, editorial reviewer: Neuro-Oncology
Selected Honors and Awards
- 1976-1977: Chief Resident, Internal Medicine, LSU, E.K. Long Hospital
1985-1987: Clinical Fellow, American Cancer Society
1997: Clinical Excellence Award, Society of Neuro-Oncology
1995-1997: Vice President, Society of Neuro-Oncology
2004-2006: President, Society of Neuro-Oncology
Selected Recent Publications
Prados MD, Chang SM, Butowski N, Deboer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, Fedoroff A, Sneed PK, Berger MS, McDermott MW, Parsa AT, Vandenberg S, James CD, Lamborn KR, Stokoe D, Haas-Kogan DA. Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma. J Clin Oncol; published online ahead of print at www.jco.org on December 15, 2008. doi: 10.1200/JCO.2008.18.9639.
Dinca EB, Lu KV, Sarkaria JN, Pieper RO, Prados MD, Haas-Kogan DA, Vandenberg SR, Berger MS, James CD. p53 Small-molecule inhibitor enhances temozolomide cytotoxic activity against intracranial glioblastoma xenografts. Cancer Res 2008;68(24):10034-9.
Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, Deangelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol 2009;91(2):183-9.
Butowski N, Chang SM, Junck L, Deangelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol 2009;91(2):175-82.
Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, Deangelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD; North American Brain Tumor Consortium. Neurooncology clinical trial design for targeted therapies: Lessons learned from the North American Brain Tumor Consortium. Neuro Oncol 2008;10(4):631-42.
Jakacki RI, Yates A, Blaney SM, Zhou T, Timmerman R, Ingle AM, Flom L, Prados MD, Adamson PC, Pollack IF. A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood. Neuro Oncol 2008;10(4):569-76.
Haas-Kogan DA, Banerjee A, Kocak M, Prados MD, Geyer JR, Fouladi M, McKnight T, Poussaint TY, Broniscer A, Blaney SM, Boyett JM, Kun LE. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol 2008;10(3):341-7.
Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD; North American Brain Tumor Consortium. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 2008;10(2):162-70.
Smith JS, Chang EF, Lamborn KR, Chang SM, Prados MD, Cha S, Tihan T, Vandenberg S, McDermott MW, Berger MS. Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas. J Clin Oncol 2008;26(8):1338-45.
Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol 2008;61(6):1059-67.
Chen AM, Chang S, Pouliot J, Sneed PK, Prados MD, Lamborn KR, Malec MK, McDermott MW, Berger MS, Larson DA. Phase I trial of gross total resection, permanent iodine-125 brachytherapy, and hyperfractionated radiotherapy for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2007;69(3):825-30.
Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, Deangelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD; for the North American Brain Tumor Consortium and the National Cancer Institute. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res 2007;13(24):7401-6
Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res 2007;13(23):7133-8.
Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG 2nd, Buckner JC, James CD, Aldape K. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 2007;25(16):2288-94.
Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, Aldape KD, Croteau DJ, Sherman JW, Puri RK; Cintredekin Besudotox Intraparenchymal Study Group. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007;25(7):837-44.
Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol 2007;81(3):271-7.
Butowski N, Lamborn KR, Berger MS, Prados MD, Chang SM. Historical controls for phase II surgically based trials requiring gross total resection of glioblastoma multiforme. J Neurooncol 2007;85(1):87-94.
Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M, Kapadia A, Rabbitt J, Page MS, Fedoroff A, Xie D, Kelley SK. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro-oncol 2006;8(1):67-78.
Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol 2006;24(22):3651-6.